Repression of Human Immunodeficiency Virus Type 1 through the Novel Cooperation of Human Factors YY1 and LSF

1998 ◽  
Vol 72 (2) ◽  
pp. 1709-1709
Author(s):  
Fabio Romerio ◽  
Matthew N. Gabriel ◽  
David M. Margolis
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Factors ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
The Novel ◽  
Immunodeficiency Virus

scholarly journals Identification of Novel HLA-A2-Restricted Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Epitopes Predicted by the HLA-A2 Supertype Peptide-Binding Motif

2001 ◽  
Vol 75 (3) ◽  
pp. 1301-1311 ◽  
Author(s):  
Marcus A. Altfeld ◽  
Brian Livingston ◽  
Neha Reshamwala ◽  
Phuong T. Nguyen ◽  
Marylyn M. Addo ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
The Novel ◽  
Immunodeficiency Virus ◽  
Hiv 1 ◽  
Ctl Responses

ABSTRACT Virus-specific cytotoxic T-lymphocyte (CTL) responses are critical in the control of human immunodeficiency virus type 1 (HIV-1) infection and will play an important part in therapeutic and prophylactic HIV-1 vaccines. The identification of virus-specific epitopes that are efficiently recognized by CTL is the first step in the development of future vaccines. Here we describe the immunological characterization of a number of novel HIV-1-specific, HLA-A2-restricted CTL epitopes that share a high degree of conservation within HIV-1 and a strong binding to different alleles of the HLA-A2 superfamily. These novel epitopes include the first reported CTL epitope in the Vpr protein. Two of the novel epitopes were immunodominant among the HLA-A2-restricted CTL responses of individuals with acute and chronic HIV-1 infection. The novel CTL epitopes identified here should be included in future vaccines designed to induce HIV-1-specific CTL responses restricted by the HLA-A2 superfamily and will be important to assess in immunogenicity studies in infected persons and in uninfected recipients of candidate HIV-1 vaccines.

Sign in / Sign up

Export Citation Format

Share Document